MATRIX METALLOPROTEINASES ON ENDOTHELIAL FUNCTION IN ATHEROSCLEROSIS

基质金属蛋白酶对动脉粥样硬化内皮功能的影响

• 批准号: 7604826
• 负责人: WILLIAM G HAYNES
• 金额: $ 0.75万
• 依托单位: UNIVERSITY OF IOWA
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-03-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7604826
• 关键词: Acute; Arterial Fatty Streak; Atherosclerosis; Computer Retrieval of Information on Scientific Projects Database; Coronary; Coronary Arteriosclerosis; Cytoskeleton; Dose; Doxycycline; Functional disorder; Funding; Gelatinase B; Grant; Institution; Lesion; Matrix Metalloproteinase Inhibitor; Matrix Metalloproteinases; Patients; Reporting; Research; Research Personnel; Resources; Source; Specimen; Syndrome; Testing; United States National Institutes of Health; Unstable angina; acute coronary syndrome; disorder prevention; inhibitor/antagonist; novel; prevent

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Matrix metalloproteinase-9 (MMP-9) has been found to be enzymatically active in atherosclerotic plaques. It was found in 83% of specimens obtained from the "culprit" coronary lesions of patients with unstable angina. Elevated levels of MMP-9 have also been reported in patients with acute coronary syndromes. These findings raise the possibility that inhibitors of MMP-9 might provide a novel form of therapy for stabilization of the atherosclerotic lesions of patients with coronary artery disease and prevention of acute ischemic syndromes. Doxycycline (even in low doses) is a specific and selective inhibitor of MMP activity and thus can prevent extra-cellular matrix destruction. We propose to test the hypothesis that endothelial function in subjects with various degrees of endothelial dysfunction will be impoved following administration of low dose doxycycline.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此，可以在其他清晰的条目中表示。列出的机构是 对于中心，这不一定是调查员的机构。 已经发现基质金属蛋白酶9（MMP-9）在动脉粥样硬化斑块中具有酶活性。 它是从83％的标本中发现的，从不稳定心绞痛的患者的“罪魁祸首”冠状动脉病变中发现。 急性冠状动脉综合征患者的MMP-9水平升高。 这些发现提出了一种可能性，即MMP-9的抑制剂可能为稳定冠状动脉疾病患者的动脉粥样硬化病变和预防急性缺血综合症的动脉粥样硬化病变提供了一种新型的治疗形式。 强力霉素（即使是低剂量）是MMP活性的特异性和选择性抑制剂，因此可以防止细胞外基质破坏。 我们建议检验以下假设：在给药低剂量强力霉素后，将障碍具有不同程度内皮功能障碍的受试者的内皮功能。